Involvement of signal transducer and activator of transcription 3 in delayed xenograft rejection in mice-to-rats cardiac transplantation as a regulator / 中华器官移植杂志

Objective To evaluate the roles of signal transducer and activator of transcription 3(STAT3) played in delayed xenograft rejection.Method Mice-to-rats cardiac xenograft model was established and recipients were administrated by inhibitor of phosphorylation of STAT3,5,15-Diphenylporphyrin(DPP),and immunosuppressive agent,ciclosporin A (CsA) alone or both.The survival of graft was analyzed.Immunohistochemistry and immunoblotting were utilized to detect the phosphorylated STAT3 (p-STAT3),and real-time polymerase chain reaction was used to assess STAT3-targeted genes in grafts.Result The expression of p-STAT3 was increased significantly with the prolonged survival in grafts (P ＜ 0.05).Administration of DPP and CsA both significantly prolonged survival of the grafts (P＜0.05),and decreased the expressions of STAT3-targeted genes including Bcl-xl,Bcl-2,Cyclin D1,C-myc and VEGF (P＜0.05).DPP and CsA exerted the synergistic effects.Conclusion STAT3,which is persistently activated in cardiac xenografts,probably up-regulates downstream genes to promote proliferation and to inhibit apoptosis of endothelial cells,leading to the activation of endothelial cells and delayed xenograft rejection.

Advances on novel estrogen receptor GPR30 / 中国癌症杂志

G protein-coupled receptor 30(GPR30) was a novel estrogen receptor identified as membrane associated receptor in the late 1990s.This new member of estrogen receptors was independent of the classic nuclear estrogen receptor ? and ? due to the low homology and signifi cant difference between them.It was reported that GPR30 localized endoplasmic reticulum predominantly,which was expressed in diverse cancer cells and a wide range of systems throughout the body.The rapid non-genetic response,partially at least,transcription regulation of estrogenic effects were mediated by the novel receptor via transactivation of epidermal growth factor receptor and modulation of second messengers such as cyclic adenosine monophosphate(cAMP) and Ca2+.These pathways,possibly coordinate with ER?,were involved in various physiological,physiopathological and carcinogenesis process.Theoretically,GPR30 would be a novel therapeutic target in estrogen-related diseases such as breast carcinoma.